Cholesterol Disorders

Oral PCSK9 Inhibitor Significantly Reduced High Levels of Cholesterol in Phase 1 Trials
November 18, 2021

AHA 2021: New research showed MK-0616, an investigative oral PCSK9 inhibitor, was associated with a near 65% decrease in LDL-C.

Remote Program Improves Blood Pressure and Cholesterol in High-risk Patients
November 16, 2021

AHA 2021: Study suggests remote hypertension and hyperlipidemia management programs may expand telehealth delivery, increase access to care, and reduce health inequities.

Sustained Weight Loss May Reverse CV Risk Factors Linked to Obesity, Study Shows
September 28, 2021

EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.

Women with T2D Less Likely to Receive Guideline-recommended Cardiovascular Care vs Men
September 28, 2021

EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.

Early LDL-C Exposure and Cumulative Burden Increase CHD Risk in Middle Age
September 24, 2021

Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.

Preventive Cardiology after Framingham: Nathan D. Wong, PhD, MPH, Details the Evolution
July 28, 2021

Nathan D Wong, PhD, MPH, renowned in the field of preventive cardiology, reviewed for Patient Care the history of the field and his own pivotal contributions and also paid tribute to his lifetime mentors.

Fundamentals of CVD Risk Assessment: Guideline Topline for Primary Care
July 28, 2021

Assessment of CVD risk is the foundation of primary prevention and integral to primary care. Brush up on the fundamental tools of risk estimation from the ACC/AHA guidelines.

Pregnancy Contraindications on Statin Labels to be Removed, per FDA Request
July 23, 2021

The FDA requests removal of pregnancy contraindication from statin prescribing information based on comprehensive reviews that found no evidence of an increase in birth defects.

Low-dose Rivaroxaban plus Aspirin Effective in CAD/PAD Regardless of Multimorbidity, Polypharmacy
July 15, 2021

In patients with stable vascular disease from the COMPASS trial, the combination of rivaroxaban and aspirin effectively reduced ischemic events despite multiple comorbidities and polypharmacy.

Study Shows Benefits of Bariatric Surgery for Mild-to-Moderate Obesity
June 14, 2021

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.